On March 17^th US New York time, global biopharmaceutical company “LakeShore biopharma”, which focuses on next-generation vaccines and biologics for treating infectious diseases and cancer, was publicly listed on the NASDAQ Stock Exchange in New York under the stock code "LSB" (formerly YS). Prior to this, the company completed business merger with Summit Healthcare Acquisition Corp on March 16th.

LakeShore biopharma has been committed to the research and commercial operation of antiviral vaccines and anti-tumor biological products for a long time. It currently has more than 800 employees and its business has expanded to China, the United States, Singapore, the United Arab Emirates, and the Philippines. Dr. Shao, Director, Co-CEO and CBO of LakeShore biopharma, led other members of the company's board of directors, management team, investors, and guests to preside over the Nasdaq listing bell ringing ceremony. "Landing on NASDAQ is an important milestone in the company's development history, as well as a celebration of the hard work and dedication of the company's management team, all employees, and business partners. At the same time, we thank the Summit Healthcare management team for their cooperation and support. Landing on NASDAQ will lay a solid foundation for the company's long-term development and further internationalization. We look forward to a more brilliant future for the company as a NASDAQ listed company," said Dr. Shao. Through the merger of LakeShore biopharma and Summit Healthcare, the company simultaneously completed approximately $36 million in equity financing. At present, investors in LakeShore biopharma include international medical professional investment institutions such as Oceanpine Capital, OrbiMed Capital, Eight Roads Capital, F-Prime Capital, CBC Group, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Gennex, Epiphron Capital, Superstring Capital, etc. Summit Healthcare CEO Tan Bo and Tong Shaojing will join the board of directors of LakeShore biopharma.